Business context and reporting period
The supplied filing is FibroGen, Inc.’s Form 10-K for the fiscal year ended December 31, 2015, filed February 29, 2016—not a filing for Kyntra Bio, Inc. This summary follows the filing. FibroGen is a clinical-stage biopharmaceutical company; its lead candidate, roxadustat, was in Phase 3 for CKD-related anemia, while FG-3019 was in Phase 2 for fibrosis and cancer indications. The filing also describes FG-5200, a corneal implant in preclinical development in China.
Financial and operating results
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Revenue | $180.8 million | $137.6 million | Up 31% |
| Operating expenses | $258.5 million | $187.7 million | Up 38% |
| Operating loss | $77.6 million | $50.1 million | Loss widened |
| Net loss | $85.8 million | $59.5 million | Loss widened |
| Net loss per share | $1.42 | $3.17 | Lower loss per share, principally reflecting more weighted-average shares after the IPO |
| Research and development | $214.1 million | $150.8 million | Up 42% |
Revenue remained collaboration-driven; FibroGen reported no revenue from approved product sales. The 2015 total included a $120 million AstraZeneca upfront payment and a $15 million development milestone, both received in Q2. AstraZeneca represented 88% of 2015 revenue and Astellas 12%. The company’s calculated operating and net margins were approximately negative 43% and negative 47%, respectively.
In Q4 2015, revenue was $24.4 million, operating expenses were $72.9 million, and net loss was $51.4 million, or $0.83 per share. Q4 2014 revenue was $16.1 million and net loss was $50.6 million. Quarterly results are affected by the timing and accounting recognition of partner payments; Q2 2015 reported net income of $57.1 million following the collaboration payments.
At December 31, 2015, cash and cash equivalents were $153.3 million; short- and long-term investments totaled $159.6 million; accounts receivable was $15.4 million; working capital was $133.4 million; and total assets were $470.6 million. Cash, cash equivalents and investments together totaled approximately $312.9 million. Operating cash flow was negative $18.6 million, versus positive $22.4 million in 2014. The company said available resources were expected to fund operations for at least 12 months.
Reported liabilities included $97.4 million of lease-financing obligations and $15.1 million of product-development obligations related to TEKES loans; the latter have no stated maturity and may be forgiven under specified conditions. Contractual future payments on lease-financing obligations were $112.5 million. No conventional bank debt balance is clearly reported in the supplied text.
Material changes, outlook and risks
- Revenue growth was more than offset by rising development and public-company costs: net loss increased from $59.5 million to $85.8 million. Roxadustat accounted for $151.3 million of 2015 R&D expense; FG-3019 accounted for $35.7 million.
- FibroGen reported that its $116.5 million cap on its share of non-China roxadustat development costs had been reached; partners Astellas and AstraZeneca were to fund future non-China CKD-anemia development and commercialization costs. China development costs were shared equally with AstraZeneca.
- Management anticipated a U.S. roxadustat NDA filing in 2018. In China, Phase 3 enrollment began in December 2015; the company anticipated initiating the NDA process in Q4 2016 and described possible approval in late 2017, subject to clinical, manufacturing and regulatory uncertainties. Management expected a European marketing application before the U.S. filing.
- Roxadustat’s Phase 3 program targeted approximately 7,000–8,000 patients for U.S./EU support and included cardiovascular MACE safety endpoints. A January 2016 safety-monitoring review recommended proceeding without protocol changes. Phase 2 findings cited by management—including anemia correction without IV iron and possible safety advantages over ESAs—were not proof of Phase 3 efficacy or safety.
- FG-3019 development remained early and included ongoing IPF, pancreatic cancer and Duchenne muscular dystrophy trials, with a NASH-related liver-fibrosis study planned. The prior hepatitis-B liver-fibrosis trial was closed after improvement in the placebo group exceeded expectations, making success unlikely. Early pancreatic-cancer and IPF signals were from small or open-label data and require controlled confirmation.
- Key risks include clinical-trial failure or delay, safety findings, reliance on two collaboration partners, partner termination rights, manufacturing and supply constraints, reimbursement and pricing uncertainty, competition, and regulatory uncertainty in China. The company warned that it expected continuing losses and might need additional financing. A potential roxadustat/statin interaction could increase statin exposure; scheduling changes did not eliminate the effect in studies.
- An $8.5 million cash-versus-short-term-investment classification error in the September 2015 interim presentation was corrected in the annual filing; management said it was not material to previously filed statements. The auditor gave an unqualified opinion and reported effective internal control over financial reporting.
Investor verification checklist
- Confirm the issuer identity: the filing is for FibroGen, Inc. (NASDAQ: FGEN), not Kyntra Bio, Inc.
- Review the audited statements and subsequent filings for liquidity, cash burn, partner receipts, and whether the stated 12-month funding outlook held.
- Track roxadustat Phase 3 enrollment, MACE results, regulatory timelines, and any safety or labeling developments, including the statin interaction.
- Verify whether China trials, manufacturing approvals, reimbursement and pricing arrangements, and the projected NDA timetable progressed as described.
- Assess FG-3019 controlled-trial evidence separately from the preliminary open-label findings, including the status of the discontinued liver-fibrosis study.
- Examine partner concentration and contingent milestone assumptions, lease obligations, TEKES loan terms, and potential dilution from outstanding options and equity awards.